Selected Publications:
Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25. : 2017.
Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.: Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6. : 2016.
Kosteva J, Langer C: The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Current Opinion in Oncology 20 (2): 155-161,2008.
Kosteva J, Langer C: Skeletal metastases: Optimal management in 2007. Supportive Care in Cancer Therapy : 2008.
Kosteva J, Langer C: The changing landscape of non-small cell lung cancer: Economic consequences of skeletal metastases. New Directions in the Treatment of Lung Cancer 1 (4): 1-9,2005.
Kosteva J, Langer C.: Skeletal metastases in NSCLC: A retrospective review. 4th Annual ECOG/Aventis Young Investigator Symposium : 2004.
Kosteva J, Langer C: Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 46 (Suppl 1): S45,2004.
Kosteva J, Langer C: Skeletal metastases of non-small cell lung cancer: Advancements in diagnosis and treatment. Lung Cancer Principles and Practice Updates 4 (2): 1-14,2004.